Key Highlights
- Bristol Myers Squibb shares are trading essentially flat, up 0.37% at $65.55, after touching an all-time high of $68.10 earlier in the session.
- The intraday spike followed a Financial Times report that AstraZeneca held preliminary merger talks with the company for a deal that could value the combined business near $400 billion.
- Shares have since pulled back to around breakeven as skepticism grows over deal completion, with some commentators calling it a possible 'fake out.'
- The merger chatter follows Bristol Myers' strong second-quarter results, which beat both revenue and EPS estimates and came with raised full-year 2026 guidance.
- Multiple analysts including JPMorgan, Citigroup, and Truist have recently lifted price targets, reflecting improving sentiment around the company's Growth Portfolio.
What's Happening With the Stock
Bristol Myers Squibb (NYSE:BMY) shares are trading essentially flat today, up 0.37% at $65.55, with a day range of $64.14 to $68.10 on volume of 20.13 million shares, despite having spiked as much as 8% in premarket trading and touched an all-time high of $68.10. The intraday move followed a Financial Times report that AstraZeneca (NYSE:AZN) held preliminary merger talks with Bristol Myers Squibb for a deal that could value the combined company at nearly $400 billion.
Shares have since pulled back to around breakeven as skepticism grows over whether the deal will ultimately be completed, with analysts flagging steep regulatory hurdles given both companies' overlapping oncology franchises. The merger chatter comes just days after Bristol Myers posted strong second-quarter results, with adjusted EPS of $2.04 beating the $1.60 estimate, while multiple analysts including JPMorgan, Citigroup, and Truist have recently lifted price targets, reflecting improving sentiment around the company's Growth Portfolio even as legacy drug patent cliffs and the Eliquis exclusivity loss in 2028 remain key overhangs.
Bristol Myers Squibb's second-quarter total revenue rose 5% year over year to approximately $13 billion, with Growth Portfolio revenue up 14% to $7.6 billion, representing nearly 60% of total revenue. Ten products in the portfolio achieved double-digit growth, including Reblozyl, Breyanzi, Camzyos, Opdualag, and Movantik. Eliquis delivered demand-driven growth of 21%, partly offsetting declines in the legacy portfolio. Diluted EPS was $2.04, with gross margin of 71.4%, operating expenses of $4.1 billion, and an effective tax rate of 16.5%.
Guidance and Pipeline
The company raised full-year 2026 guidance for both revenue and adjusted diluted EPS, citing higher projected Eliquis revenue growth of 20% to 25% and a less pronounced legacy portfolio decline, now expected between 4% and 6%, while maintaining projections for gross margin, other income and expense, and tax rate. Several near-term regulatory and data milestones were highlighted, including an FDA target action date of August 17, 2026, for iberdomide in multiple myeloma, with the company positioned for launch readiness.
Bristol Myers Squibb's balance sheet remained strong, with approximately $11.5 billion in cash, cash equivalents, and marketable securities as of June 30. The company generated approximately $3.4 billion in operating cash flow during the second quarter and paid down $1.2 billion in debt, while continuing to prioritize business development, dividend payments, and disciplined capital allocation. Recent AI partnerships with Anthropic and Nvidia were also announced to support research and development and enterprise operations.
Bristol Myers Squibb's market capitalization stood at $133.82 billion intraday, with shares trading at a trailing price-to-earnings ratio of 11.05 and a dividend yield of 3.83%. The stock's 52-week range spans $42.52 to $68.10, with today's session high representing a fresh all-time high before the pullback.
Conclusion
Bristol Myers Squibb's round trip from an all-time high back to roughly flat reflects the market's uncertainty over whether reported AstraZeneca merger talks will ultimately result in a deal, layered on top of what was already a strong earnings-driven improvement in sentiment. With regulatory hurdles and integration complexity likely to weigh on any formal announcement, the stock's underlying momentum from its Growth Portfolio and raised guidance may prove to be the more durable story regardless of how the merger speculation resolves.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...